Edition:
United Kingdom

Qiagen Launches Companion Diagnostic Using FGFR Alterations To Help Guide Treatment Of Metastatic Urothelial Cancer


Friday, 12 Apr 2019 

April 12 (Reuters) - Qiagen NV ::QIAGEN LAUNCHES FIRST FDA-APPROVED COMPANION DIAGNOSTIC USING FGFR ALTERATIONS TO HELP GUIDE THE TREATMENT OF METASTATIC UROTHELIAL CANCER.QIAGEN NV - NOVEL THERASCREEN FGFR RGQ RT-PCR KIT WILL AID IN IDENTIFYING PATIENTS ELIGIBLE FOR TREATMENT WITH BALVERSA, DEVELOPED BY JANSSEN.